In:
PLOS Pathogens, Public Library of Science (PLoS), Vol. 17, No. 2 ( 2021-2-3), p. e1008859-
Abstract:
Severe fever with thrombocytopenia syndrome (SFTS) caused by a species Dabie bandavirus (formerly SFTS virus [SFTSV]) is an emerging hemorrhagic infectious disease with a high case-fatality rate. One of the best strategies for preventing SFTS is to develop a vaccine, which is expected to induce both humoral and cellular immunity. We applied a highly attenuated but still immunogenic vaccinia virus strain LC16m8 (m8) as a recombinant vaccine for SFTS. Recombinant m8s expressing SFTSV nucleoprotein (m8-N), envelope glycoprotein precursor (m8-GPC), and both N and GPC (m8-N+GPC) in the infected cells were generated. Both m8-GPC- and m8-N+GPC-infected cells were confirmed to produce SFTSV-like-particles (VLP) in vitro , and the N was incorporated in the VLP produced by the infection of cells with m8-N+GPC. Specific antibodies to SFTSV were induced in mice inoculated with each of the recombinant m8s, and the mice were fully protected from lethal challenge with SFTSV at both 10 3 TCID 50 and 10 5 TCID 50 . In mice that had been immunized with vaccinia virus strain Lister in advance of m8-based SFTSV vaccine inoculation, protective immunity against the SFTSV challenge was also conferred. The pathological analysis revealed that mice immunized with m8-GPC or m8-N+GPC did not show any histopathological changes without any viral antigen-positive cells, whereas the control mice showed focal necrosis with inflammatory infiltration with SFTSV antigen-positive cells in tissues after SFTSV challenge. The passive serum transfer experiments revealed that sera collected from mice inoculated with m8-GPC or m8-N+GPC but not with m8-N conferred protective immunity against lethal SFTSV challenge in naïve mice. On the other hand, the depletion of CD8-positive cells in vivo did not abrogate the protective immunity conferred by m8-based SFTSV vaccines. Based on these results, the recombinant m8-GPC and m8-N+GPC were considered promising vaccine candidates for SFTS.
Type of Medium:
Online Resource
ISSN:
1553-7374
DOI:
10.1371/journal.ppat.1008859
DOI:
10.1371/journal.ppat.1008859.g001
DOI:
10.1371/journal.ppat.1008859.g002
DOI:
10.1371/journal.ppat.1008859.g003
DOI:
10.1371/journal.ppat.1008859.g004
DOI:
10.1371/journal.ppat.1008859.g005
DOI:
10.1371/journal.ppat.1008859.g006
DOI:
10.1371/journal.ppat.1008859.g007
DOI:
10.1371/journal.ppat.1008859.g008
DOI:
10.1371/journal.ppat.1008859.g009
DOI:
10.1371/journal.ppat.1008859.g010
DOI:
10.1371/journal.ppat.1008859.g011
DOI:
10.1371/journal.ppat.1008859.t001
DOI:
10.1371/journal.ppat.1008859.t002
DOI:
10.1371/journal.ppat.1008859.t003
DOI:
10.1371/journal.ppat.1008859.t004
DOI:
10.1371/journal.ppat.1008859.s001
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2205412-1
Permalink